Skip to main content
Apyx Medical Corp logo

Apyx Medical Corp — Investor Relations & Filings

Ticker · APYX ISIN · US0323472052 LEI · 5299009QZVYUYO082S45 US Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2018-09-10 Director's Dealing
Country US United States of America
Listing US APYX

About Apyx Medical Corp

https://apyxmedical.com/

Apyx Medical Corporation is an advanced energy technology company that develops, manufactures, and markets innovative products for surgical and cosmetic markets. The company's proprietary Helium Plasma Platform, which is the foundation for its Renuvion® and J-Plasma® brands, utilizes a unique combination of helium plasma and radiofrequency (RF) energy. These systems are designed to deliver controlled energy for the cutting, coagulation, and ablation of soft tissue, with a primary focus on aesthetic procedures for skin tightening and body contouring. Apyx Medical, formerly Bovie Medical, leverages its expertise in energy-based waveforms to provide transformative solutions for surgeons and their patients.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2018-09-10 English
FORM 4
Director's Dealing
2018-09-10 English
FORM 4
Director's Dealing
2018-09-10 English
BVX_8-K_2018.09.05
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events that shareholders should know about. The text mentions an "Item 8.01 - Other Events" section describing a press release about updated financial guidance following a segment sale transaction. It also references an exhibit containing the press release. The document is relatively short (3058 characters) and primarily serves as an announcement of an event and a press release attachment rather than containing detailed financial statements or comprehensive analysis. Therefore, it is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a certification or officer attestation. Given the nature of the filing and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like 8-Ks that do not fit other specific categories.
2018-09-05 English
BVX_8-K_2018.08.30
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the completion of an asset sale transaction, departure of a director/officer, voting results from the annual meeting, and other related disclosures. It is not a full annual or quarterly report, nor is it a transcript or presentation. The document reports on management changes (departure of President and Director), voting results, and a significant capital transaction (asset sale). However, the primary purpose is to disclose these events as they occur, which is typical for an 8-K filing. According to the classification rules, such filings are best categorized under Regulatory Filings (RNS) as they do not fit into more specific categories like MANG (management changes) or CAP (capital updates) alone, since the 8-K covers multiple event types and is a general regulatory announcement. The document length and detail confirm it is not a mere announcement of a report but a regulatory filing reporting multiple material events.
2018-08-30 English
BVX_10-Q_2018.Q2
Interim / Quarterly Report Q2 2018
2018-08-01 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.